Simple Summary Portal hypertension (PH) and hepatocellular carcinoma (HCC) are major
complications of liver cirrhosis with a detrimental impact on patient outcomes that share …

Portal hypertension (PHT) and hepatocellular carcinoma (HCC) often coexist, and their
association impairs the prognosis of patients with cirrhosis. The interplay between these two …

Abstract Background and Aims Portal hypertension (PHT) and hepatocellular carcinoma
(HCC) are major complication of cirrhosis which significantly contribute to morbidity and …

Results: Recent therapeutic advances observed in the management of HCC, notably
through the advent of immunotherapy, have led to a clear improvement in the survival of …

Portal hypertension (PHT) is the main determinant of liver cirrhosis decompensation, defined
by the occurrence of ascites, variceal bleeding or hepatic encephalopathy. 1, 2 A portal …

Background Portal hypertension (PHT) and hepatocellular carcinoma (HCC) are two major
complications of cirrhosis that are closely linked and impact patients prognosis, particularly …

Aim Atezolizumab plus bevacizumab combination therapy (Atezo+ Beva) is used as the first‐
line therapy for unresectable hepatocellular carcinoma (u‐HCC). Serious adverse events …

Background Portal hypertension (PHT) often complicates hepatocellular carcinoma (HCC)
treatment and prognosis. We aimed to assess PHT's impact on AtezoBev outcomes and …

One other concern is primary prophylaxis in case of NSBB contraindication or intolerance. In
patients treated with bevacizumab, EBL is the alternative to NSBBs, but we have to keep in …

Surgical resection is not indicated in patients with portal hypertension in the current
guideline of B arcelona Clinic Liver Cancer (BCLC) stage. We report a systematic review …